OBJECTIVE: This open-label, randomized controlled trial investigated the effects of cilnidipine, an L/N-type calcium channel blocker (CCB), in patients with chronic kidney disease (CKD). METHODS: Sixty patients with CKD and well-controlled hypertension being treated with a reninangiotensin system (RAS) inhibitor and an L-type CCB (L-CCB) were randomly assigned either to switch from the L-CCB to cilnidipine after a 4-week observation period or to continue with L-CCB treatment. Blood pressure, heart rate and renal function were monitored for 12 months. Data were available for analysis from 50 patients: 24 from the cilnidipine group and 26 from the L-CCB group. RESULTS: Blood pressure was well controlled in both groups. After 12 months, proteinuria and heart rate were significantly decreased in the cilnidipine group, but proteinuria increased and heart rate remained unchanged in the L-CCB group. There was a significant positive correlation between the percentage changes in proteinuria and heart rate. CONCLUSIONS: Cilnidipine has antihypertensive effects equivalent to those of L-CCBs. In patients with CKD, proteinuria can be decreased by switching from an L-CCB to cilnidipine, thereby improving renal function.
Introduction
Renin-angiotensin system (RAS) inhibitors such as angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers (ARBs) are widely recognized to be effective renoprotective agents for hypertensive subjects with proteinuria. 1 -3 In the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) 4 and the Japanese Society of Hypertension Guidelines for the Management of Hypertension 2009 (JSH 2009), 5 RAS inhibitors are recommended as a first-choice treatment for hypertensive patients with chronic kidney disease (CKD) but, as the effects of RAS inhibitors on blood pressure are mild, it is sometimes difficult to reduce blood pressure to the target level using these agents. Calcium channel blockers (CCBs) are widely used to treat hypertensive patients and their effectiveness for blood pressure control has been confirmed. 6 In our clinical practice in Japan, a CCB is often added to an RAS inhibitor if blood pressure remains higher than the 130/80 mmHg level recommended in the JSH 2009 guidelines. 5 However, CCBs may increase proteinuria, thereby worsening renal function. 1, 7, 8 In particular, CCBs acting on the L-type calcium channels (L-CCBs) dilate afferent arterioles, 9 leading to an increase in glomerular filtration rate (GFR).
The dihydropyridine CCB cilnidipine, which exerts its effects on sympathetic nerve terminals and blocks L-as well as N-type calcium channels (L/N-CCB) controlling the release of catecholamines, 10 -12 was developed in Japan. In addition to its blood pressurelowering effects, it has also been shown to inhibit any increase in catecholamines in the blood due to increased reflex sympathetic nervous activity and reflex tachycardia in animal experiments and hypertensive patients. 13 -16 Cilnidipine has been classified as a fourth-generation CCB based on its actions on sympathetic neurotransmitter release. 17 Moreover, this drug dilates both afferent and efferent glomerular arterioles in murine models of nephrosclerosis and hydronephrosis. 18, 19 Because this dilative effect is inhibited in the presence of ω-conotoxins, which are selective N-type calcium channel inhibitors, cilnidipine is thought to dilate efferent glomerular arterioles by blocking the N-type calcium channels. 20 This mechanism of action involving blockade of the N-type calcium channels may lead to a reduction in glomerular hyperfiltration and proteinuria, and thereby improve renal function. Proteinuria has been reported to be an independent risk factor for progressive renal dysfunction. 3, 20, 21 The addition of an efferent arteriole dilator such as an L/N-CCB to therapy with an RAS inhibitor could diminish glomerular hyperfiltration, leading to decreased proteinuria and improvement in renal function. To date, it has been reported that cilnidipine exerts renal protective effects in hypertension and diabetic nephropathy, 22 -27 but no previously reported study has investigated the influence of cilnidipine on renal function compared with that of L-CCBs in patients with CKD who have already achieved a normal blood pressure. In addition, previous reports have not addressed the relationship between the sympathoinhibitory and renoprotective effects of cilnidipine.
The present study investigated the effects on renal function after switching from an L-CCB to cilnidipine in hypertensive patients in whom treatment with an RAS inhibitor and an L-CCB had resulted in blood pressures within the normal range. This 12 -month open-label, randomized controlled trial was conducted at four m 2 ), calculated using the formula established by Cockcroft and Gault, 28 who had been treated with an RAS inhibitor and an L-CCB for > 2 months were recruited to the study. All patients had well-controlled hypertension, with a target blood pressure in the clinic of < 130/80 mmHg. Patients with uncontrolled hypertension (> 140/90 mmHg), those undergoing dialysis, those > 85 years old and < 20 years old, patients not taking RAS inhibitors, those with severe heart failure or with severe liver dysfunction were excluded from the study. Patients who the clinicians thought to be inappropriate, for example having social and financial problem or with mental disorders, were also excluded.
Patients and methods

PATIENTS
The study protocol was approved by the Ethics Committee of Kyoto Prefectural University of Medicine, Kyoto, Japan. Patients were given a detailed explanation of the study protocol and aims before being enrolled and written consent was obtained.
TREATMENT PROTOCOL
After a 4-week observation period during which patients continued their normal treatment, patients were randomly divided either to be switched to receive 10 mg/day cilnidipine (L/N-type CCB) or to continue to receive their same L-CCB; patients were assigned to the two groups according to the day they entered the study, with those entering on even-numbered days being assigned to the cilnidipine group and those entering on odd-numbered days being assigned to the L-CCB group. Because the present study was performed in patients with CKD who had achieved sufficient blood pressure control, for ethical reasons the drugs were switched without a washout period ( Fig.  1 ). This was an open-label study in which patients and investigators were not blinded to the drugs used.
Blood pressure was controlled at < 130/80 mmHg (mean of two clinic measurements). The doses of L-CCB and cilnidipine could be altered to ensure adequate control of blood pressure, with a dose of up to 20 mg/day cilnidipine being allowed in patients switched to this agent. In both groups, administration of diuretics and α 1 -blockers was also allowed to help maintain blood pressure at < 130/80 mmHg. The type and dosage of RAS inhibitor was not changed during the study period. Other drugs affecting renal function and proteinuria were prohibited. Any adverse effects were reported and, if seen in the cilnidipine group, administration of cilnidipine would be immediately stopped, those patients would be withdrawn and switched back to their previous L-CCB (no such adverse events were seen).
PATIENT MONITORING
Blood pressure, heart rate, proteinuria and serum creatinine were measured in all patients before and 6 and 12 months after switching the L-CCB. Heart rate, an indicator of sympathetic nervous activity, was measured using an automated sphygmomanometer, with simultaneous measurement of blood pressure. Proteinuria was measured in urine by one of the two following methods depending on the medical institution: (i) the pyrogallol red T Hatta, K Takeda, Y Shiotsu et al.
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method with simultaneous measurement of urinary creatinine concentration by enzymelinked immunosorbent assay to give the urinary protein-to-creatinine ratio, or (ii) by measuring protein excretion in a 24-h urine sample. Because the correlation between g protein/g creatinine in single voided urine samples and g protein/24-h is high, 29 ,30 the values measured by these two methods were judged to be equivalent. Serum creatinine concentration was measured using an enzymatic assay method. Haemoglobin A 1c was measured at baseline by highperformance liquid chromatography.
STATISTICAL ANALYSES
All data were expressed as the mean ± SE when applicable. The correlation between the percentage change from baseline in heart rate and proteinuria was analysed using Spearman's rank correlation coefficient. Differences between variables were evaluated using the Student's unpaired t-test and the Mann-Whitney U-test. A Pvalue < 0.05 was considered to be statistically significant. All statistical analyses were performed using StatView ® software version 5.0 (SAS Institute Inc., Cary, NC, USA).
Results
A total of 60 patients with CKD and wellcontrolled hypertension were enrolled in the study and randomized to the two treatments. Ten patients were lost to follow up; of the remaining 50 patients, 24 were randomized to be switched to cilnidipine and 26 remained on their current L-CCB. Patients' baseline demographic and clinical characteristics are summarized in Table 1 . There were no significant differences in age, sex, body mass index, systolic and diastolic blood pressure, heart rate, estimated GFR, serum creatinine concentration, haemoglobin A 1c , and aetiology of renal disease between the two groups.
Baseline proteinuria was significantly worse in the group to be switched to cilnidipine than in those who were to remain on L-CCB (P < 0.05). Dosages for the three types of L-CCB used in the study were: amlodipine, mean of 8.6 mg/day (range 5 -10 mg/day) in the cilnidipine group and 8.5 mg/day (range 5 -10 mg/day) in the L-CCB group; nifedipine, 40 mg/day for all patients in both groups; benidipine, 4 mg/day in the cilnidipine group only. There were no significant intergroup differences in the type of concomitant RAS inhibitor or L-CCB employed during the observation period; valsartan and candesartan were prescribed at the maximum doses approved in Japan (12 and 160 mg/day, respectively).
There were no significant differences in blood pressure between the two groups at baseline (Table 1) or at 12 months (cilnidipine group 128.5/71.8 mmHg; L-CCB group 129.7/73.6 mmHg).
Mean serum creatinine concentration did not change significantly during the treatment period in patients switched to cilnidipine, being 1.81 mg/dl at baseline and 1.98 mg/dl at 12 months, but increased significantly from 1.91 mg/dl at baseline to 2.88 mg/dl at 12 months in patients who remained on their L-CCB (P < 0.01; Fig. 2A ). 
TABLE 1: Baseline demographic and clinical characteristics of the patients with chronic kidney disease and well-controlled hypertension who received a renin-angiotensin system (RAS) inhibitor plus either cilnidipine (an L/N-type calcium channel blocker) or L-type calcium channel blocker (L-CCB)
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As a percentage, this represented an increase in serum creatinine concentration from baseline to 12 months of 6.2% in patients switched to cilnidipine compared with 32.6% in those who remained on their L-CCB (P < 0.01; Fig. 2B ).
Mean urinary protein excretion decreased significantly from 1.96 g/day (or g/g· creatinine) at baseline to 0.95 g/day (g/g· creatinine) at 12 months in patients switched to cilnidipine (P < 0.001), while it increased significantly from 1.23 g/day (g/g·creatinine) at baseline to 2.10 g/day (g/g·creatinine) in the L-CCB group (P < 0.001; Fig. 3A ). As a percentage change from baseline, this represented a decrease in proteinuria at 12 months of 15.9% in the cilnidipine group compared with an increase of 55.4% in patients who remained on their L-CCB (P < 0.001; Fig. 3B ). Although mean urinary protein was significantly lower in the L-CCB group than in the cilnidipine group before the medication switch (P < 0.05; Table 1) , it was significantly lower in patients 12 months after the switch to cilnidipine than in those who remained on their L-CCB (0.95 ± 0.23 versus 2.10 ± 0.51 g/day [g/g·creatinine], respectively; P < 0.001).
Heart rate decreased significantly from baseline to 12 months in patients switched to cilnidipine (mean 78.3 versus 68.9 beats/min, respectively; P < 0.01), but not in those who remained on their L-CCB (80.8 versus 81.8 beats/min, respectively; Fig. 4 ); percentage changes in heart rate from baseline to 12 months being a 12% decrease and a 1.0% increase in the cilnidipine and L-CCB groups, respectively (significant intergroup difference, P < 0.01).
Regression analysis of the percentage changes in urinary protein excretion and heart rate in the two groups showed a significant positive correlation between these two parameters (r = 0.5186, P = 0.0003; Fig.  5 ). There was no significant difference in the regression slopes calculated for each group 
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separately, which indicated that the relationship between these two parameters was independent of the drug type used. Patients switched to cilnidipine mostly showed decreases in heart rate and urinary protein excretion, whereas those who remained on their L-CCB mostly showed increases in these two parameters. No adverse events were observed in either group during the 12-month study period.
Discussion
In hypertensive patients with concomitant CKD, strict antihypertensive therapy is one of the most important treatments. As many epidemiological studies have demonstrated that CKD is a major risk factor for cardiovascular disease, 31 -34 anti hyper tensive therapy must be aimed at renoprotection as well as blood pressure control. Although RAS inhibitors are the first-line drugs for antihypertensive therapy in patients with CKD, many patients require multidrug treatment to achieve blood pressure targets. In such cases, CCBs, with their strong hypotensive effects, are often concomitantly used, 35 but their effects on renal microcirculation haemodynamics and urinary protein excretion vary according to the type of CCB. 9 It is, therefore, necessary to determine which antihypertensive drugs are most appropriate from the viewpoint of renal protection.
Several reports have indicated that the proteinuria-lowering effect of cilnidipine is superior to that of L-type CCBs. 22, 24, 25, 27 In the present study, all patients in both groups achieved target blood pressure, but switching from L-CCBs to cilnidipine led to reduction in urinary protein excretion and suppression of any serum creatinine increase at the end of the 12-month study period. These findings suggest that the renoprotective effect of cilnidipine is independent of its blood 
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pressure-lowering effect. Cilnidipine is known to exert a dilatative effect on efferent renal arterioles 18,19 and its proteinurialowering effect is, therefore, likely to result from an improvement in glomerular filtration via a decrease in intraglomerular pressure associated with efferent arteriolar dilatation. The efferent arteriolar dilatative action of cilnidipine is thought to be due to inhibition of sympathetic nervous activity by blockade of N-type calcium channels. 19 The ARBs are also known to dilate efferent arterioles 36 but, as they were used at their maximum doses in the present study, the efferent arterioles were probably already dilated at the start of cilnidipine treatment. The renoprotective effects obtained with cilnidipine were likely to be due to further dilatation of the efferent arterioles via a different mechanism from that involving RAS inhibition. This possibility was supported by the correlation observed in the present study between the change in heart rate and the change in urinary protein excretion in the patients switched to cilnidipine.
As well as there being a significant correlation between the change in heart rate and the change in proteinuria in the present study, patients switched to cilnidipine showed a marked decrease in heart rate after 12 months, indicating that sympathetic nervous activity was inhibited by cilnidipine. One of the mechanisms by which cilnidipine may decrease urinary protein excretion may, therefore, be by inhibition of sympathetic nervous activity. Many patients who were switched to cilnidipine showed a reduced heart rate and it has been reported previously that cilnidipine significantly suppresses tachycardia, suggesting that the inhibitory effects of this drug on N-type calcium channels are more strongly expressed in subjects showing raised sympathetic nervous activity. 37 The blockade of N-type calcium channels by cilnidipine may, therefore, more readily decrease intraglomerular pressure in patients with increased sympathetic nervous activity. Enhanced sympathetic nervous activity has been reported in patients with CKD 38 and, as the switch to cilnidipine occurred with no prior washout period in the present study, patients with higher sympathetic nervous activity were targeted and this probably contributed to the significant decrease in heart rate in the cilnidipine group.
The Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Disease Study showed a reduction in urinary protein excretion in the cilnidipine group, 22 but did not clarify the relationship between the decrease in heart rate and the reduction in urinary protein excretion. In the present study, blood pressure was controlled from the start, thus probably accounting for the clear relationship between inhibition of sympathetic nervous activity and reduction of proteinuria by cilnidipine. These current findings suggest that the N-type calcium channel blockade caused by cilnidipine occurred more easily in hypertensive patients with concomitant CKD than the L-type blockade caused by L-CCBs, which resulted in a clear difference in renoprotective effects in comparison with the L-CCB group.
Serum creatinine concentrations at 12 months were elevated in the group of patients who remained on their L-CCB but not in the group that was switched to cilnidipine in the present study. Patients with well-controlled blood pressure were chosen for the study in order to rule out any influence of hypotensive effects on intraglomerular pressure. As proteinuria was markedly reduced after 12 months in the group switched to cilnidipine but not in the L-CCB group, it can be assumed that T Hatta, K Takeda, Y Shiotsu et al. Renoprotection by cilnidipine in chronic kidney disease cilnidipine reduced intraglomerular pressure independently of any decrease in systemic blood pressure. In addition, because these changes in the group switched to cilnidipine were insidious, there was no apparent serum creatinine elevation. However, the L-CCB patients showed increased proteinuria, suggesting that no intraglomerular pressure reduction effects independent of hypotensive effects can be expected with L-CCBs and that serum creatinine concentrations are likely to increase in patients with persistent urinary protein excretion.
Proteinuria itself is a risk factor for renal impairment. 3, 20, 21 Simultaneous use of cilnidipine may, therefore, suppress the progression of renal impairment. In addition, cilnidipine, but not the L-CCB amlodipine, has been reported to inhibit expression of cell adhesion factor intercellular adhesion molecule-1 in the glomerulus and to reduce glomerular hypertrophy and renal interstitial fibrosis in a rat model of metabolic syndrome. 39 Moreover, cilnidipine inhibits von Willebrand factor in Dahl salt-sensitive rats with high salt loading and mesangial matrix expansion in cultured rat mesangial cells. 40, 41 There is a possibility that these effects also contributed to the significant differences in proteinuria and renal function between the two groups of patients in the present study.
Cilnidipine is said to be a fourthgeneration CCB in terms of its effects on sympathetic nervous activity. 17 Renoprotective effects exceeding those of conventional CCBs also occurred in the present study, which means that cilnidipine may also be considered to be a fourthgeneration CCB from the viewpoint of organ protection. The present results suggest that, if combination therapy with RAS inhibitors and CCBs is attempted for hypertensive patients with concomitant CKD, the CCB should be switched to cilnidipine in those achieving the target blood pressure, especially if urinary protein excretion persists.
The present study had a number of limitations. First, home blood pressures or 24-h blood pressures were not measured, so the possibility that there may have been differences in blood pressure values apart from those detected in the clinic between the L-CCB and cilnidipine groups cannot be excluded. Blood pressure measured in a medical examination room is affected by various stress factors and is not necessarily an accurate reflection of the true value. In addition, blood pressure fluctuations have a major influence on proteinuria, so further studies should evaluate renal function after showing that home blood pressures or 24-h blood pressures are comparable with those determined at the clinic. Secondly, heart rate was only measured in the medical examination room, but should be evaluated using 24-h monitoring. Moreover, although heart rate was evaluated as an indicator of sympathetic nervous activity, it is also affected by parasympathetic nervous activity. For this reason, further analysis of heart rate fluctuations or evaluation of blood or urinary catecholamines is needed. Thirdly, this was an open-label study involving a small number of patients over a 12-month treatment period. Large-scale multicentre randomized studies are necessary to examine whether the renoprotective effects observed in the L/Ntype CCB (cilnidipine) group will reduce cardiovascular events. Finally, because of a significant difference in baseline urinary protein excretion between the two groups, there is a possibility that the rate of change in urinary protein excretion induced by cilnidipine was overestimated.
In conclusion, the present study confirmed Ca 2+ channel blocker with inhibitory action on sympathetic neurotransmitter release. Renoprotection by cilnidipine in chronic kidney disease that the L/N-type CCB, cilnidipine, has antihypertensive effects equivalent to those of L-CCBs. In addition, when using the maximum doses of RAS inhibitors in patients with CKD, proteinuria can be further decreased by switching from an L-CCB to cilnidipine, thereby improving renal function.
